Literature DB >> 15882952

High-level expression and purification of a nonmitogenic form of human acidic fibroblast growth factor in Escherichia coli.

Xiaoping Wu1, Zhijian Su, Xiaokun Li, Qing Zheng, Yadong Huang, Hui Yuan.   

Abstract

To decrease the potential side effects of acidic fibroblast growth factor (aFGF) caused by its broad-spectrum mitogenic activity, a nonmitogenic form of aFGF (nhaFGF), which retained the cardio- and neuroprotective characters of the wild-type aFGF, was overexpressed in Escherichia coli. The expression level of nhaFGF was up to 25% of the total cellular protein. The expressed nhaFGF was purified by ionic exchange and heparin affinity chromatography from the supernatant of bacteria lysate. The mitogenic activity of the purified nhaFGF was decreased dramatically comparable to that of the wild-type aFGF (haFGF) detected by methylthiazoletetrazolium method. The purified recombinant nhaFGF was sufficiently prepared and sufficient for the following pharmacological study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882952     DOI: 10.1016/j.pep.2004.07.021

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

1.  Effects of temperature and additives on stability and spectrum of a therapeutic fibroblast growth factor.

Authors:  Cy Zhou; X Guo; St Wang; Yp Zhu; Dz Mu
Journal:  Daru       Date:  2011       Impact factor: 3.117

2.  Large-Scale Preparation of Highly Stable Recombinant Human Acidic Fibroblast Growth Factor in Escherichia coli BL21(DE3) plysS Strain.

Authors:  Bingjieu Yu; Wenzhe Sun; Zhen Huang; Gang Sun; Le Li; Jiawei Gu; Mengying Zheng; Xiaokun Li; ChangJu Chun; Qi Hui; Xiaojie Wang
Journal:  Front Bioeng Biotechnol       Date:  2021-04-13

3.  The international effort: building the bridge for Translational Medicine: Report of the 1st International Conference of Translational Medicine (ICTM).

Authors:  Xiaoming Chen; Roland Andersson; William Cs Cho; David Christiani; Richard Coico; Jeffery Drazen; Markus Ege; Thomas Fehniger; Hongwei Gao; Kunlin Jin; Michael N Liebman; Elena Lopez; Giuseppe Marraro; Gyorgy Marko-Varga; Francesco M Marincola; Laurentiu M Popescu; Claudio Spada; Aamir Shahzad; Ena Wang; Wei Wang; Xiangdong Wang; Yong-Xiao Wang; Jinglin Xia; Jia Qu
Journal:  Clin Transl Med       Date:  2012-08-14

4.  The prevention of diabetic cardiomyopathy by non-mitogenic acidic fibroblast growth factor is probably mediated by the suppression of oxidative stress and damage.

Authors:  Chi Zhang; Linbo Zhang; Shali Chen; Biao Feng; Xuemian Lu; Yang Bai; Guang Liang; Yi Tan; Minglong Shao; Melissa Skibba; Litai Jin; Xiaokun Li; Subrata Chakrabarti; Lu Cai
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

5.  Large-scale production of bioactive recombinant human acidic fibroblast growth factor in transgenic silkworm cocoons.

Authors:  Feng Wang; Riyuan Wang; Yuancheng Wang; Ping Zhao; Qingyou Xia
Journal:  Sci Rep       Date:  2015-11-16       Impact factor: 4.379

6.  Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction.

Authors:  Xin-Qiao Tian; Xian-Wei Ni; He-Lin Xu; Lei Zheng; De-Li ZhuGe; Bin Chen; Cui-Tao Lu; Jian-Jun Yuan; Ying-Zheng Zhao
Journal:  Int J Nanomedicine       Date:  2017-09-26

7.  Non-Mitogenic Fibroblast Growth Factor 1 Enhanced Angiogenesis Following Ischemic Stroke by Regulating the Sphingosine-1-Phosphate 1 Pathway.

Authors:  Yuchi Zou; Jian Hu; Wenting Huang; Shasha Ye; Fanyi Han; Jingting Du; Mingjie Shao; Ruili Guo; Jingjing Lin; Yeli Zhao; Ye Xiong; Xue Wang
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.